Clinic
Emergency Hospital Systems LLC
Emergency Hospital Systems LLC was paid $25.74M by Medicaid between Jun 2020 and Dec 2024, across 32 billing codes. Its largest line is 99284, emergency room visit (serious) — 81% of everything it billed.
33Billing provider infoEMERGENCY HOSPITAL SYSTEMS LLC
CLEVELAND, TX 77327
CLEVELAND, TX 77327
33aNPI1992172019assigned 08/24/2015
33bProvider typeAmbulatory Surgical Clinic/Center
28Total paid$25.74M
24GClaims68,263
24DCodes billed32
24AFirst – last monthJun 2020 – Dec 2024
Compared with peers
Next to other Ambulatory Surgical Clinic/Center providers in Texas
Rank by total paid#19 of 320
Median peer was paid$205K
This provider vs. median126×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 1,625 | $55K | |
| 2021 | 17,519 | $662K | |
| 2022 | 25,042 | $4.79M | |
| 2023 | 17,333 | $17.46M | |
| 2024incomplete | 6,744 | $2.77M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 81% | 21,586 | 12,183 | $20.87M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 15% | 4,210 | 2,470 | $3.83M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 1.7% | 7,539 | 4,109 | $433K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.1% | 7,107 | 6,836 | $284K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 13,200 | 6,285 | $158K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 6,435 | 6,107 | $69K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,295 | 1,140 | $27K |
| 86328 | <1% | 781 | 745 | $26K | |
| 0001A | <1% | 332 | 309 | $9K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 1,475 | 1,292 | $6K |
| 80053 | Comprehensive metabolic panel | <1% | 1,008 | 894 | $6K |
| 0002A | <1% | 141 | 131 | $4K |
20 more codes
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 495 | $4K |
| 71045 | Radiologic examination, chest; single view | <1% | 179 | $3K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 149 | $3K |
| 87807 | <1% | 261 | $3K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 103 | $2K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 113 | $2K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 26 | $2K |
| 81003 | <1% | 1,053 | $1K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 276 | $1K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 60 | $871.84 |
| 81025 | <1% | 165 | $726.02 | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 38 | $696.06 |
| G9498 | Antibiotic regimen prescribed | <1% | 16 | $302.37 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 91 | $261.68 |
| 84484 | <1% | 19 | $70.02 | |
| 82553 | <1% | 19 | $64.89 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 39 | $61.05 |
| 82550 | <1% | 19 | $36.59 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 13 | $1.84 |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | 0% | 20 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBANSAL, SHANTI (MANAGER)
| Provider | Location | Paid |
|---|---|---|
| Houston Heart Rhythm PLLC | Houston, TX | $79K |
| Octagos Health INC. | Houston, TX | $69K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.